We performed the first manufacturer-independent evaluation of the fully automated sample-to-result two-target test cobas 6800 SARS-CoV-2.The comparator was a standardized 3-h SARS-CoV-2 protocol, consisting of RNA extraction using an automated portable instrument, followed by a two-target reverse transcription real-time PCR (RT-PCR), which our laboratory has routinely used since January 2020. Our results showed that cobas is a reliable assay for qualitative detection of SARS-CoV-2 in nasopharyngeal swab samples collected in the Universal Transport Medium System.
COBISS.SI-ID: 19397379
Due to the need for faster turnaround time for priority patients, we evaluated the Cepheid Xpert Xpress SARS-CoV-2 test and compared it with the existing Roche SARS-CoV-2 test on the cobas 6800 system. The specificity of the test is 100% and the sensitivity 95.5.% compared to the cobas 6800 system. The main advantage of the test is shown in the short turnaround time from sample acceptance to the result, as it was one hour, compared to the cobas system, which takes 3 to 5 hours.
COBISS.SI-ID: 44784899
Accurate anti-SARS-CoV-2 assays are needed to inform diagnostic, therapeutic, and public health decisions. The first manufacturer-independent head-to-head comparison of two rapid high-throughput automated electrochemiluminescence double-antigen sandwich immunoassays targeting total anti-SARS-CoV-2 antibodies against two different viral proteins, Elecsys Anti-SARS-CoV-2 (Elecsys-N) and Elecsys Anti-SARS-CoV-2 S (Elecsys-S) (Roche Diagnostics), was performed in a routine setting during the exponential growth phase of the epidemic’s second wave.
COBISS.SI-ID: 61796611